NCRA
Nocera, Inc.
Packaged Foods
Market Cap$2M
5Y Perf.-96.3%
Build Your Comparison
Side-by-side financial analysisNCRA
LIXT
Try popular comparisons:
Stock Comparison
NCRA vs LIXT
Revenue, margins, valuation, and 5-year total return — side by side.
LIXT
Lixte Biotechnology Holdings, Inc.
Biotechnology
Market Cap$76M
5Y Perf.-77.0%
NCRA vs LIXT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  NCRA |  LIXT |
|---|---|---|
| Industry | Packaged Foods | Biotechnology |
| Market Cap | $2M | $76M |
| Revenue (TTM) | $11M | $0.00 |
| Net Income (TTM) | $-4M | $-7M |
| Gross Margin | 1.4% | — |
| Operating Margin | -25.2% | — |
| Total Debt | $7M | $664K |
| Cash & Equiv. | $8M | $5M |
NCRA vs LIXT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NCRA
LIXT
| Stock | Jan 21 | Jun 26 | Return |
|---|---|---|---|
| Nocera, Inc. (NCRA) | 100 | 3.7 | -96.3% |
| Lixte Biotechnology… (LIXT) | 100 | 23.0 | -77.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NCRA vs LIXT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LIXT leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Nocera, Inc. is the stronger pick specifically for operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇LIXT emerged as the overall leader. Track its performance:
NCRA
Nocera, Inc.
The Niche Pick
NCRA is the clearest fit if your priority is efficiency.
- -52.5% ROA vs LIXT's -96.3%, ROIC -70.0% vs -121.5%
Best for: efficiency
LIXT
Lixte Biotechnology Holdings, Inc.
The Income Pick
LIXT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.19
- EPS growth 20.8%
- -22.2% 10Y total return vs NCRA's -97.4%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  LIXT | 152.8% revenue growth vs NCRA's -35.2% |
| Quality / Margins | LIXT | -0.0% margin vs NCRA's -34.0% |
| Stability / Safety | LIXT | Beta 1.19 vs NCRA's 1.68, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | LIXT | +407.2% vs NCRA's -83.7% |
| Efficiency (ROA) |  NCRA | -52.5% ROA vs LIXT's -96.3%, ROIC -70.0% vs -121.5% |
NCRA vs LIXT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLIXTLAGGINGNCRA
NCRANocera, Inc.
0leads
LIXTLixte Biotechnology H…
4leads
6 Total Categories
CATEGORYLEADERvs NCRAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LIXT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LIXT5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
LIXT6/6
Risk & VolatilityBeta, volatility, and downside exposure
LIXT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LIXT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NCRA and LIXT operate at a comparable scale, with $11M and $0 in trailing revenue.
| Metric | NCRANocera, Inc. | LIXTLixte Biotechnolo… |
|---|---|---|
| RevenueTrailing 12 months | $11M | $0 |
| EBITDAEarnings before interest/tax | -$3M | -$7M |
| Net IncomeAfter-tax profit | -$4M | -$7M |
| Free Cash FlowCash after capex | -$3M | -$4M |
| Gross MarginGross profit ÷ Revenue | +1.4% | — |
| Operating MarginEBIT ÷ Revenue | -25.2% | — |
| Net MarginNet income ÷ Revenue | -34.0% | — |
| FCF MarginFCF ÷ Revenue | -26.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -49.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -3.9% | +37.9% |
LIXT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — NCRA and LIXT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | NCRANocera, Inc. | LIXTLixte Biotechnolo… |
|---|---|---|
| Market CapShares × price | $2M | $76M |
| Enterprise ValueMkt cap + debt − cash | $2M | $72M |
| Trailing P/EPrice ÷ TTM EPS | -0.84x | -5.56x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.22x | — |
| Price / BookPrice ÷ Book value/share | 1.09x | 30.91x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — NCRA and LIXT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
LIXT leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
LIXT delivers a -113.2% return on equity — every $100 of shareholder capital generates $-113 in annual profit, vs $-132 for NCRA. LIXT carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to NCRA's 3.31x. On the Piotroski fundamental quality scale (0–9), LIXT scores 4/9 vs NCRA's 3/9, reflecting mixed financial health.
| Metric | NCRANocera, Inc. | LIXTLixte Biotechnolo… |
|---|---|---|
| ROE (TTM)Return on equity | -132.0% | -113.2% |
| ROA (TTM)Return on assets | -52.5% | -96.3% |
| ROICReturn on invested capital | -70.0% | -121.5% |
| ROCEReturn on capital employed | -35.9% | -83.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 3.31x | 0.06x |
| Net DebtTotal debt minus cash | -$697,307 | -$4M |
| Cash & Equiv.Liquid assets | $8M | $5M |
| Total DebtShort + long-term debt | $7M | $664,491 |
| Interest CoverageEBIT ÷ Interest expense | — | -1217.29x |
LIXT leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
LIXT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LIXT five years ago would be worth $2,265 today (with dividends reinvested), compared to $343 for NCRA. Over the past 12 months, LIXT leads with a +407.2% total return vs NCRA's -83.7%. The 3-year compound annual growth rate (CAGR) favors LIXT at 1.8% vs NCRA's -51.6% — a key indicator of consistent wealth creation.
| Metric | NCRANocera, Inc. | LIXTLixte Biotechnolo… |
|---|---|---|
| YTD ReturnYear-to-date | -80.3% | +82.3% |
| 1-Year ReturnPast 12 months | -83.7% | +407.2% |
| 3-Year ReturnCumulative with dividends | -88.7% | +5.6% |
| 5-Year ReturnCumulative with dividends | -96.6% | -77.3% |
| 10-Year ReturnCumulative with dividends | -97.4% | -22.2% |
| CAGR (3Y)Annualised 3-year return | -51.6% | +1.8% |
LIXT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
LIXT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LIXT is the less volatile stock with a 1.19 beta — it tends to amplify market swings less than NCRA's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIXT currently trades 93.3% from its 52-week high vs NCRA's 7.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NCRANocera, Inc. | LIXTLixte Biotechnolo… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 1.19x |
| 52-Week HighHighest price in past year | $2.40 | $7.50 |
| 52-Week LowLowest price in past year | $0.16 | $0.64 |
| % of 52W HighCurrent price vs 52-week peak | +7.0% | +93.3% |
| RSI (14)Momentum oscillator 0–100 | 40.8 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 7.2M | 89K |
LIXT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NCRANocera, Inc. | LIXTLixte Biotechnolo… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LIXT leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallLixte Biotechnology Holding… (LIXT)Leads 4 of 6 categories
Loading custom metrics...
NCRA vs LIXT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — NCRA or LIXT?
Over the past 5 years, Lixte Biotechnology Holdings, Inc.
(LIXT) delivered a total return of -77. 3%, compared to -96. 6% for Nocera, Inc. (NCRA). Over 10 years, the gap is even starker: LIXT returned -22. 2% versus NCRA's -97. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — NCRA or LIXT?
By beta (market sensitivity over 5 years), Lixte Biotechnology Holdings, Inc.
(LIXT) is the lower-risk stock at 1. 19β versus Nocera, Inc. 's 1. 68β — meaning NCRA is approximately 41% more volatile than LIXT relative to the S&P 500. On balance sheet safety, Lixte Biotechnology Holdings, Inc. (LIXT) carries a lower debt/equity ratio of 6% versus 3% for Nocera, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — NCRA or LIXT?
On earnings-per-share growth, the picture is similar: Lixte Biotechnology Holdings, Inc.
grew EPS 20. 8% year-over-year, compared to -11. 1% for Nocera, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — NCRA or LIXT?
Lixte Biotechnology Holdings, Inc.
(LIXT) is the more profitable company, earning 0. 0% net margin versus -25. 7% for Nocera, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIXT leads at 0. 0% versus -22. 3% for NCRA. At the gross margin level — before operating expenses — NCRA leads at 1. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — NCRA or LIXT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is NCRA or LIXT better for a retirement portfolio?
For long-horizon retirement investors, Lixte Biotechnology Holdings, Inc.
(LIXT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 19)). Nocera, Inc. (NCRA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LIXT: -22. 2%, NCRA: -97. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between NCRA and LIXT?
These companies operate in different sectors (NCRA (Consumer Defensive) and LIXT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.